Stereotaxis Competitors

BioLife Solutions (NASDAQ:BLFS) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares BioLife Solutions and Stereotaxis' revenue, earnings per share (EPS) and valuation.

BioLife Solutions has higher earnings, but lower revenue than Stereotaxis. Stereotaxis is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

67.7% of BioLife Solutions shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 22.3% of BioLife Solutions shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

BioLife Solutions has a beta of 1.55, meaning that its share price is 55% more volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares BioLife Solutions and Stereotaxis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for BioLife Solutions and Stereotaxis, as provided by MarketBeat.com.

BioLife Solutions currently has a consensus target price of $46.6667, suggesting a potential upside of 48.10%. Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given BioLife Solutions' higher probable upside, research analysts clearly believe BioLife Solutions is more favorable than Stereotaxis.

Summary

BioLife Solutions beats Stereotaxis on 10 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares Natus Medical and Stereotaxis' revenue, earnings per share (EPS) and valuation.

Stereotaxis has lower revenue, but higher earnings than Natus Medical. Stereotaxis is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

89.7% of Natus Medical shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 1.5% of Natus Medical shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Risk and Volatility

Natus Medical has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Profitability

This table compares Natus Medical and Stereotaxis' net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of current ratings for Natus Medical and Stereotaxis, as provided by MarketBeat.com.

Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given Stereotaxis' stronger consensus rating and higher probable upside, analysts clearly believe Stereotaxis is more favorable than Natus Medical.

AxoGen (NASDAQ:AXGN) and Stereotaxis (NYSEAMERICAN:STXS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and profitability.

Analyst Recommendations

This is a summary of current ratings for AxoGen and Stereotaxis, as provided by MarketBeat.com.

AxoGen currently has a consensus target price of $23.75, suggesting a potential upside of 29.92%. Stereotaxis has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Given AxoGen's higher probable upside, research analysts clearly believe AxoGen is more favorable than Stereotaxis.

Valuation & Earnings

This table compares AxoGen and Stereotaxis' revenue, earnings per share (EPS) and valuation.

Stereotaxis has lower revenue, but higher earnings than AxoGen. Stereotaxis is trading at a lower price-to-earnings ratio than AxoGen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AxoGen has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, Stereotaxis has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500.

Insider and Institutional Ownership

78.4% of AxoGen shares are held by institutional investors. Comparatively, 54.3% of Stereotaxis shares are held by institutional investors. 6.9% of AxoGen shares are held by insiders. Comparatively, 34.9% of Stereotaxis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AxoGen and Stereotaxis' net margins, return on equity and return on assets.

Stereotaxis (NYSEAMERICAN:STXS) and Semler Scientific (OTCMKTS:SMLR) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and Semler Scientific, as provided by MarketBeat.com.

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. Semler Scientific has a consensus target price of $110.50, suggesting a potential upside of 3.39%. Given Stereotaxis' higher probable upside, equities analysts plainly believe Stereotaxis is more favorable than Semler Scientific.

Valuation and Earnings

This table compares Stereotaxis and Semler Scientific's revenue, earnings per share and valuation.

Semler Scientific has higher revenue and earnings than Stereotaxis. Stereotaxis is trading at a lower price-to-earnings ratio than Semler Scientific, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Semler Scientific has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 12.1% of Semler Scientific shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 13.6% of Semler Scientific shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and Semler Scientific's net margins, return on equity and return on assets.

Summary

Semler Scientific beats Stereotaxis on 8 of the 12 factors compared between the two stocks.

Stereotaxis (NYSEAMERICAN:STXS) and TransMedics Group (NASDAQ:TMDX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and TransMedics Group, as provided by MarketBeat.com.

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. TransMedics Group has a consensus target price of $44.20, suggesting a potential upside of 76.52%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Stereotaxis.

Valuation and Earnings

This table compares Stereotaxis and TransMedics Group's revenue, earnings per share and valuation.

Stereotaxis has higher revenue and earnings than TransMedics Group. Stereotaxis is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 76.7% of TransMedics Group shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 13.1% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and TransMedics Group's net margins, return on equity and return on assets.

Summary

Stereotaxis beats TransMedics Group on 8 of the 14 factors compared between the two stocks.

Stereotaxis (NYSEAMERICAN:STXS) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, analyst recommendations, profitability and dividends.

Analyst Ratings

This is a summary of current recommendations and price targets for Stereotaxis and ViewRay, as provided by MarketBeat.com.

Stereotaxis currently has a consensus target price of $8.00, suggesting a potential upside of 4.17%. ViewRay has a consensus target price of $4.50, suggesting a potential upside of 14.21%. Given ViewRay's higher probable upside, analysts plainly believe ViewRay is more favorable than Stereotaxis.

Valuation and Earnings

This table compares Stereotaxis and ViewRay's revenue, earnings per share and valuation.

Stereotaxis has higher earnings, but lower revenue than ViewRay. Stereotaxis is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Stereotaxis has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

54.3% of Stereotaxis shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 34.9% of Stereotaxis shares are held by insiders. Comparatively, 15.5% of ViewRay shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Stereotaxis and ViewRay's net margins, return on equity and return on assets.

Summary

Stereotaxis beats ViewRay on 9 of the 14 factors compared between the two stocks.